Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

From Catalytic Antibodies to Antibody-Drug Conjugates.

Dimitrov DS.

Cell Chem Biol. 2019 Sep 19;26(9):1200-1201. doi: 10.1016/j.chembiol.2019.09.006.

PMID:
31539504
2.

Optimization and Diagnostic Evaluation of Monoclonal Antibody-based Blocking ELISA Formats for Detection of Neutralizing Antibodies to Hendra Virus in Mammalian Sera.

Di Rubbo A, McNabb L, Klein R, White JR, Colling A, Dimitrov DS, Broder C, Middleton D, Lunt R.

J Virol Methods. 2019 Sep 9:113731. doi: 10.1016/j.jviromet.2019.113731. [Epub ahead of print]

PMID:
31513861
3.

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav5685. doi: 10.1126/scitranslmed.aav5685.

PMID:
31391322
4.

Rapid elimination of broadly neutralizing antibodies correlates with treatment failure in the acute phase of SHIV infection.

Wu Y, Xue J, Wang C, Li W, Wang L, Chen W, Prabakaran P, Kong D, Jin Y, Hu D, Wang Y, Lei C, Yu D, Tu C, Bardhi A, Sidorov I, Ma L, Goldstein H, Qin C, Lu L, Jiang S, Dimitrov DS, Ying T.

J Virol. 2019 Aug 2. pii: JVI.01077-19. doi: 10.1128/JVI.01077-19. [Epub ahead of print]

PMID:
31375583
5.

Optimization of the C-Terminus of an Autonomous Human IgG1 CH2 Domain for Stability and Aggregation Resistance.

Gao X, Conard A, Yang C, Zhan Y, Zeng F, Shi J, Li W, Dimitrov DS, Gong R.

Mol Pharm. 2019 Aug 5;16(8):3647-3656. doi: 10.1021/acs.molpharmaceut.9b00544. Epub 2019 Jul 22.

PMID:
31282682
6.

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Hu D, Zhu Z, Li S, Deng Y, Wu Y, Zhang N, Puri V, Wang C, Zou P, Lei C, Tian X, Wang Y, Zhao Q, Li W, Prabakaran P, Feng Y, Cardosa J, Qin C, Zhou X, Dimitrov DS, Ying T.

PLoS Pathog. 2019 Jun 26;15(6):e1007836. doi: 10.1371/journal.ppat.1007836. eCollection 2019 Jun.

7.

Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis.

Hu Y, Wang B, Shen J, Low SA, Putt KS, Niessen HWM, Matteson EL, Murphy L, Ruppert C, Jansen G, Oliver SJ, Feng Y, Dimitrov DS, Nickerson-Nutter C, Low PS.

Arthritis Res Ther. 2019 Jun 7;21(1):143. doi: 10.1186/s13075-019-1912-0.

8.

Chemometric Assessment of Soil Pollution and Pollution Source Apportionment for an Industrially Impacted Region around a Non-Ferrous Metal Smelter in Bulgaria.

Dimitrov DS, Nedyalkova MA, Donkova BV, Simeonov VD.

Molecules. 2019 Mar 2;24(5). pii: E883. doi: 10.3390/molecules24050883.

9.

Cartilage-Targeted IGF-1 Treatment to Promote Longitudinal Bone Growth.

Lui JC, Colbert M, Cheung CSF, Ad M, Lee A, Zhu Z, Barnes KM, Dimitrov DS, Baron J.

Mol Ther. 2019 Mar 6;27(3):673-680. doi: 10.1016/j.ymthe.2019.01.017. Epub 2019 Feb 1.

PMID:
30765323
10.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.

Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17.

PMID:
30655315
11.

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, Zhu Z, Dimitrov DS, Dropulic B, Orentas RJ.

Front Oncol. 2018 Nov 22;8:539. doi: 10.3389/fonc.2018.00539. eCollection 2018.

12.

A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.

Chen Z, Liu J, Chu D, Shan Y, Ma G, Zhang H, Zhang XD, Wang P, Chen Q, Deng C, Chen W, Dimitrov DS, Zhao Q.

Int J Biol Sci. 2018 May 21;14(7):799-806. doi: 10.7150/ijbs.25928. eCollection 2018.

13.

Recombinant-fully-human-antibody decorated highly-stable far-red AIEdots for in vivo HER-2 receptor-targeted imaging.

Wu Y, Chen Z, Zhang P, Zhou L, Jiang T, Chen H, Gong P, Dimitrov DS, Cai L, Zhao Q.

Chem Commun (Camb). 2018 Jun 28;54(53):7314-7317. doi: 10.1039/c8cc03037e.

PMID:
29904764
14.

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, Seaman S, Dunleavey JM, Hsu KS, Yu GJ, Morris H, Swing DA, Haines DC, Wang Y, Hwang J, Feng Y, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Dimitrov DS, St Croix B.

J Clin Invest. 2018 Jul 2;128(7):2927-2943. doi: 10.1172/JCI120481. Epub 2018 Jun 4.

15.

A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells.

Kong D, Wang Y, Ji P, Li W, Ying T, Huang J, Wang C, Wu Y, Wang Y, Chen W, Hao Y, Hong K, Shao Y, Dimitrov DS, Jiang S, Ma L.

AIDS. 2018 Aug 24;32(13):1749-1761. doi: 10.1097/QAD.0000000000001869.

PMID:
29762173
16.

Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category.

Boliar S, Patil S, Shukla BN, Ghobbeh A, Deshpande S, Chen W, Guenaga J, Dimitrov DS, Wyatt RT, Chakrabarti BK.

Virology. 2018 Jun;519:99-105. doi: 10.1016/j.virol.2018.04.002. Epub 2018 May 11.

17.

N-terminal α-amino group modification of antibodies using a site-selective click chemistry method.

Li DZ, Han BN, Wei R, Yao GY, Chen Z, Liu J, Poon TCW, Su W, Zhu Z, Dimitrov DS, Zhao Q.

MAbs. 2018 Jul;10(5):712-719. doi: 10.1080/19420862.2018.1463122.

18.

In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires.

Hong B, Wu Y, Li W, Wang X, Wen Y, Jiang S, Dimitrov DS, Ying T.

Front Immunol. 2018 Feb 5;9:128. doi: 10.3389/fimmu.2018.00128. eCollection 2018.

19.

Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.

Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS.

Front Immunol. 2017 Nov 13;8:1554. doi: 10.3389/fimmu.2017.01554. eCollection 2017. Review.

20.

Human monoclonal antibodies as candidate therapeutics against emerging viruses.

Jin Y, Lei C, Hu D, Dimitrov DS, Ying T.

Front Med. 2017 Dec;11(4):462-470. doi: 10.1007/s11684-017-0596-6. Epub 2017 Nov 20. Review.

PMID:
29159596
21.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

22.

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin.

Yu F, Song H, Wu Y, Chang SY, Wang L, Li W, Hong B, Xia S, Wang C, Khurana S, Feng Y, Wang Y, Sun Z, He B, Hou D, Manischewitz J, King LR, Song Y, Min JY, Golding H, Ji X, Lu L, Jiang S, Dimitrov DS, Ying T.

Cell Host Microbe. 2017 Oct 11;22(4):471-483.e5. doi: 10.1016/j.chom.2017.08.011. Epub 2017 Sep 28.

23.

Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM.

Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.

24.

Graphene Oxide-Polycarbonate Track-Etched Nanosieve Platform for Sensitive Detection of Human Immunodeficiency Virus Envelope Glycoprotein.

Nehra A, Chen W, Dimitrov DS, Puri A, Singh KP.

ACS Appl Mater Interfaces. 2017 Sep 27;9(38):32621-32634. doi: 10.1021/acsami.7b12103. Epub 2017 Sep 13.

PMID:
28876042
25.

One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells.

Li W, Wu Y, Kong D, Yang H, Wang Y, Shao J, Feng Y, Chen W, Ma L, Ying T, Dimitrov DS.

Sci Rep. 2017 Aug 22;7(1):9130. doi: 10.1038/s41598-017-07966-3.

26.

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein.

Bardhi A, Wu Y, Chen W, Li W, Zhu Z, Zheng JH, Wong H, Jeng E, Jones J, Ochsenbauer C, Kappes JC, Dimitrov DS, Ying T, Goldstein H.

J Virol. 2017 Sep 27;91(20). pii: e00937-17. doi: 10.1128/JVI.00937-17. Print 2017 Oct 15.

27.

Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Li N, Fu H, Hewitt SM, Dimitrov DS, Ho M.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6623-E6631. doi: 10.1073/pnas.1706055114. Epub 2017 Jul 24.

28.

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.

Qi Q, Wang Q, Chen W, Du L, Dimitrov DS, Lu L, Jiang S.

Emerg Microbes Infect. 2017 Jun 21;6(6):e59. doi: 10.1038/emi.2017.46.

29.

Precision immunomedicine.

Ying T, Wen Y, Dimitrov DS.

Emerg Microbes Infect. 2017 Apr 26;6(4):e25. doi: 10.1038/emi.2017.22. No abstract available.

30.

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S, Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR, Dimitrov DS, St Croix B.

Cancer Cell. 2017 Apr 10;31(4):501-515.e8. doi: 10.1016/j.ccell.2017.03.005.

31.

Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets.

van Doremalen N, Falzarano D, Ying T, de Wit E, Bushmaker T, Feldmann F, Okumura A, Wang Y, Scott DP, Hanley PW, Feldmann H, Dimitrov DS, Munster VJ.

Antiviral Res. 2017 Jul;143:30-37. doi: 10.1016/j.antiviral.2017.03.025. Epub 2017 Apr 5.

PMID:
28389142
32.

Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains.

Qi Q, Wang Q, Chen W, Yu F, Du L, Dimitrov DS, Lu L, Jiang S.

J Infect. 2017 Jul;75(1):68-71. doi: 10.1016/j.jinf.2017.03.006. Epub 2017 Mar 18. No abstract available.

PMID:
28322889
33.

Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.

Li D, Gong R, Zheng J, Chen X, Dimitrov DS, Zhao Q.

Biochem Biophys Res Commun. 2017 Apr 1;485(2):446-453. doi: 10.1016/j.bbrc.2017.02.058. Epub 2017 Feb 13.

PMID:
28202413
34.

Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.

Pincus SH, Song K, Maresh GA, Hamer DH, Dimitrov DS, Chen W, Zhang MY, Ghetie VF, Chan-Hui PY, Robinson JE, Vitetta ES.

J Virol. 2017 Jan 18;91(3). pii: e01955-16. doi: 10.1128/JVI.01955-16. Print 2017 Feb 1.

35.

Identification of high-affinity anti-CD16A allotype-independent human antibody domains.

Li W, Yang H, Dimitrov DS.

Exp Mol Pathol. 2016 Oct;101(2):281-289. doi: 10.1016/j.yexmp.2016.10.001. Epub 2016 Oct 3.

PMID:
27712994
36.

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection.

Agrawal AS, Ying T, Tao X, Garron T, Algaissi A, Wang Y, Wang L, Peng BH, Jiang S, Dimitrov DS, Tseng CT.

Sci Rep. 2016 Aug 19;6:31629. doi: 10.1038/srep31629.

37.

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.

J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.

38.

Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.

Chen W, Bardhi A, Feng Y, Wang Y, Qi Q, Li W, Zhu Z, Dyba MA, Ying T, Jiang S, Goldstein H, Dimitrov DS.

MAbs. 2016 May-Jun;8(4):761-74. doi: 10.1080/19420862.2016.1160180. Epub 2016 Mar 10.

39.

Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection.

Houser KV, Gretebeck L, Ying T, Wang Y, Vogel L, Lamirande EW, Bock KW, Moore IN, Dimitrov DS, Subbarao K.

J Infect Dis. 2016 May 15;213(10):1557-61. doi: 10.1093/infdis/jiw080. Epub 2016 Mar 3.

40.

Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes.

Feng Y, Wang Y, Zhu Z, Li W, Sussman RT, Randall M, Bosse KR, Maris JM, Dimitrov DS.

MAbs. 2016 May-Jun;8(4):799-810. doi: 10.1080/19420862.2016.1155014. Epub 2016 Feb 24.

41.

High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

Lynn RC, Feng Y, Schutsky K, Poussin M, Kalota A, Dimitrov DS, Powell DJ Jr.

Leukemia. 2016 Jun;30(6):1355-64. doi: 10.1038/leu.2016.35. Epub 2016 Feb 22.

42.

A systems approach to HIV-1 vaccines.

Ying T, Prabakaran P, Dimitrov DS.

Nat Biotechnol. 2016 Jan;34(1):44-6. doi: 10.1038/nbt.3456. No abstract available.

PMID:
26744981
43.

The INNs and outs of antibody nonproprietary names.

Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.

MAbs. 2016;8(1):1-9. doi: 10.1080/19420862.2015.1114320.

44.

Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody.

Ying T, Prabakaran P, Du L, Shi W, Feng Y, Wang Y, Wang L, Li W, Jiang S, Dimitrov DS, Zhou T.

Nat Commun. 2015 Sep 15;6:8223. doi: 10.1038/ncomms9223.

45.

No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses.

Dimitrov DS, Jiang S, Ying T, Tseng CT, Zhang L, Yuen KY.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):E5115. doi: 10.1073/pnas.1513441112. Epub 2015 Aug 28. No abstract available.

46.

Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus.

Ying T, Li W, Dimitrov DS.

J Infect Dis. 2016 Mar 15;213(6):877-9. doi: 10.1093/infdis/jiv381. Epub 2015 Jul 22. No abstract available.

47.

Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn.

Ying T, Wang Y, Feng Y, Prabakaran P, Gong R, Wang L, Crowder K, Dimitrov DS.

MAbs. 2015;7(5):922-30. doi: 10.1080/19420862.2015.1067353.

48.

Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies.

Yang Z, Li J, Liu Q, Yuan T, Zhang Y, Chen LQ, Lou Q, Sun Z, Ying H, Xu J, Dimitrov DS, Zhang MY.

PLoS One. 2015 May 26;10(5):e0126428. doi: 10.1371/journal.pone.0126428. eCollection 2015.

49.

A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.

Zhao Q, Tran H, Dimitrov DS, Cheung NK.

Int J Cancer. 2015 Nov 1;137(9):2243-52. doi: 10.1002/ijc.29588. Epub 2015 May 19.

50.

Assessment of folate receptor-β expression in human neoplastic tissues.

Shen J, Putt KS, Visscher DW, Murphy L, Cohen C, Singhal S, Sandusky G, Feng Y, Dimitrov DS, Low PS.

Oncotarget. 2015 Jun 10;6(16):14700-9.

Supplemental Content

Loading ...
Support Center